Two Sigma Advisers’s Aptose Biosciences, Inc. APTO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-157
Closed -$45.1K 2753
2023
Q1
$45.1K Sell
157
-96
-38% -$27.9K ﹤0.01% 2461
2022
Q4
$66K Sell
253
-53
-17% -$14.2K ﹤0.01% 2339
2022
Q3
$82K Sell
306
-85
-22% -$29.3K ﹤0.01% 2334
2022
Q2
$131K Sell
391
-391
-50% -$187K ﹤0.01% 2358
2022
Q1
$479K Buy
782
+160
+26% +$88.5K ﹤0.01% 2006
2021
Q4
$378K Buy
622
+386
+164% +$363K ﹤0.01% 2055
2021
Q3
$232K Sell
236
-85
-26% -$106K ﹤0.01% 2200
2021
Q2
$480K Sell
321
-153
-32% -$333K ﹤0.01% 1955
2021
Q1
$1.27M Sell
474
-110
-19% -$218K ﹤0.01% 1515
2020
Q4
$1.15M Sell
584
-65
-10% -$153K ﹤0.01% 1502
2020
Q3
$1.75M Sell
649
-36
-5% -$89.8K 0.01% 1230
2020
Q2
$1.94M Buy
685
+19
+3% +$61.3K 0.01% 1214
2020
Q1
$1.78M Sell
666
-4
-0.6% -$11.9K 0.01% 1177
2019
Q4
$1.71M Buy
670
+460
+219% +$599K ﹤0.01% 1297
2019
Q3
$197K Buy
210
+109
+108% +$124K ﹤0.01% 2045
2019
Q2
$118K Buy
101
+58
+135% +$53.4K ﹤0.01% 2197
2019
Q1
$39K Sell
43
-1
-2% -$905 ﹤0.01% 2240
2018
Q4
$38K Hold
44
﹤0.01% 2291
2018
Q3
$51K Hold
44
﹤0.01% 2175
2018
Q2
$78K Buy
+44
New +$70.1K ﹤0.01% 2288

Other funds holding APTO

Two Sigma Advisers's APTO Position: Q2 2023 in Review

Two Sigma Advisers sold out of Aptose Biosciences, Inc. (APTO) in Q2 2023, closing a stake of 157 shares — an estimated $45.1K sold.

Two Sigma Advisers first reported a position in APTO in Q2 2018 and held it in 20 quarters. The position peaked at $1.94M in Q2 2020. 24 funds tracked by Wall St. Rank hold APTO as of Q2 2023.

  • Two Sigma Advisers reported no remaining Aptose Biosciences, Inc. position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 157 Aptose Biosciences, Inc. shares in Q2 2023, an estimated $45.1K.
  • Two Sigma Advisers first reported a position in Aptose Biosciences, Inc. in Q2 2018 and held it in 20 quarters.
  • Two Sigma Advisers's Aptose Biosciences, Inc. position peaked at $1.94M in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.